Korobelnik JF, Larsen M, Eter N, et al. - In this open-label, Phase 4 clinical study (CENTERA), researchers tested the safety and effectiveness of intravitreal aflibercept (IVT-AFL) treat-and-extend (T&E) dosing in patients with macular edema secondary to central retinal vein occlusion (CRVO). Patients underwent 2mg IVT-AFL at baseline and every 4 weeks until the requirements for disease stability were met (or until Wk20), at which point treatment intervals were adjusted in 2-wk increments based on functional and anatomic outcomes. IVT-AFL T&E dosing has achieved clinically meaningful improvements in functional and anatomic outcomes. The last actual and last intended treatment interval of ≥ 8 wks was completed by the majority of patients, so treatment intervals could have been further expanded with a longer study period.